Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. by Shiraishi Kouya et al.
Association of variations in HLA class II and
other loci with susceptibility to EGFR-mutated
lung adenocarcinoma.
著者 Shiraishi Kouya, Okada Yukinori, Takahashi
Atsushi, Kamatani Yoichiro, Momozawa Yukihide,
Ashikawa Kyota, Kunitoh Hideo, Matsumoto
Shingo, Takano Atsushi, Shimizu Kimihiro, Goto
Akiteru, Tsuta Koji, Watanabe Shun-Ichi, Ohe
Yuichiro, Watanabe Yukio, Goto Yasushi,
Nokihara Hiroshi, Furuta Koh, Yoshida Akihiko,
Goto Koichi, Hishida Tomoyuki, Tsuboi
Masahiro, Tsuchihara Katsuya, Miyagi Yohei,
Nakayama Haruhiko, Yokose Tomoyuki, Tanaka
Kazumi, Nagashima Toshiteru, Ohtaki Yoichi,
Maeda Daichi, Imai Kazuhiro, Minamiya
Yoshihiro, Sakamoto Hiromi, Saito Akira,
Shimada Yoko, Sunami Kuniko, Saito Motonobu,
Inazawa Johji, Nakamura Yusuke, Yoshida
Teruhiko, Yokota Jun, Matsuda Fumihiko, Matsuo
Keitaro, Daigo Yataro, Kubo Michiaki, Kohno
Takashi
journal or
publication title
Nature communications
volume 7
page range 12451
year 2016-08-09
URL http://hdl.handle.net/10422/00012326
doi: 10.1038/ncomms12451
(C) The Author(s) 2016. This work is licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material
in this article are included in the article's Creative Commons license, unless
indicated otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from the 
license holder to reproduce the material. To view a copy of this license, 
visit http://creativecommons.org/licenses/by/4.0/
ARTICLE
Received 1 Jan 2016 | Accepted 24 Jun 2016 | Published 9 Aug 2016
Association of variations in HLA class II and other
loci with susceptibility to EGFR-mutated lung
adenocarcinoma
Kouya Shiraishi1, Yukinori Okada2,3,4, Atsushi Takahashi4,5, Yoichiro Kamatani4, Yukihide Momozawa6,
Kyota Ashikawa6, Hideo Kunitoh7, Shingo Matsumoto8, Atsushi Takano9,10, Kimihiro Shimizu11, Akiteru Goto12,
Koji Tsuta13,14, Shun-ichi Watanabe15, Yuichiro Ohe16, Yukio Watanabe15, Yasushi Goto16, Hiroshi Nokihara16,
Koh Furuta17,18, Akihiko Yoshida13, Koichi Goto19, Tomoyuki Hishida20, Masahiro Tsuboi20, Katsuya Tsuchihara8,
Yohei Miyagi21, Haruhiko Nakayama22, Tomoyuki Yokose23, Kazumi Tanaka11, Toshiteru Nagashima11, Yoichi Ohtaki11,
Daichi Maeda12, Kazuhiro Imai24, Yoshihiro Minamiya24, Hiromi Sakamoto25, Akira Saito26, Yoko Shimada1,
Kuniko Sunami1,17, Motonobu Saito1, Johji Inazawa27,28,29, Yusuke Nakamura30, Teruhiko Yoshida25, Jun Yokota31,
Fumihiko Matsuda32, Keitaro Matsuo33, Yataro Daigo9,10, Michiaki Kubo6 & Takashi Kohno1
Lung adenocarcinoma driven by somatic EGFRmutations is more prevalent in East Asians (30–50%)
than in European/Americans (10–20%). Here we investigate genetic factors underlying the risk of
this disease by conducting a genome-wide association study, followed by two validation studies, in
3,173 Japanese patients with EGFR mutation-positive lung adenocarcinoma and 15,158 controls. Four
loci, 5p15.33 (TERT), 6p21.3 (BTNL2), 3q28 (TP63) and 17q24.2 (BPTF), previously shown to be
strongly associated with overall lung adenocarcinoma risk in East Asians, were re-discovered as loci
associated with a higher susceptibility to EGFR mutation-positive lung adenocarcinoma. In addition,
two additional loci, HLA class II at 6p21.32 (rs2179920; P ¼ 5.1 10 17, per-allele OR¼ 1.36) and
6p21.1 (FOXP4) (rs2495239; P¼ 3.9 10 9, per-allele OR¼ 1.19) were newly identiﬁed as loci
associated with EGFR mutation-positive lung adenocarcinoma. This study indicates that multiple
genetic factors underlie the risk of lung adenocarcinomas with EGFR mutations.
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L
ung adenocarcinoma (LADC) is the most common type of
lung cancer worldwide, with incidence and mortality rates
increasing in both Asian and Western countries. Recent
genome studies have subdivided LADC into several categories,
with mutually exclusive activations of responsible driver onco-
genes1–3. One subset of LADC is characterized by mutations in
the gene encoding epidermal growth factor receptor (EGFR), a
second with mutations in the Kirsten rat sarcoma viral oncogene
homologue (KRAS) and a third with ALK, ROS1 or RET fusion,
as well as other subcategories. EGFR mutations are present in
30–50% of LADCs in East Asian patients, a much higher
frequency than in Caucasians (10–20%)4,5. A high proportion of
patients with EGFR mutation-positive LADC are never-smokers
and females, making the development of a preventive method
critical4,6–8. Advanced LADCs with EGFR mutations are often
inoperable and are treated with tyrosine kinase inhibitors;
however, these tumours frequently become drug resistant,
leading to disease progress and death9. Understanding the
genetic factors underlying the development of LADC with
EGFR mutation is required to elucidate disease aetiology and to
identify effective methods of prevention.
Genome-wide association studies (GWASs) on lung cancer in
populations of East Asian and European countries have
found that several loci are associated with the risk of LDAC.
These include loci at chromosomes 15q25.1 (CHRNAs:
cholinergic receptor, nicotinic, alpha)10–13, 5p15.33 (TERT:
telomerase reverse transcriptase)10,11,14–16, 3q28 (TP63: tumour
protein p63)10,14–16, 6p21.3 (BTNL2: butyrophilin-like 2)14,
10q25.1 (VTI1A: vesicle transport through interaction with
t-SNAREs 1A)15 and 17q24.2 (BPTF: bromodomain PHD
ﬁnger transcription factor)14. Although a TERT polymorphism
was reported to be associated with the risk of non-small cell lung
cancer with the EGFR mutation17, inherited genetic factors
underlying the risk for LADC with the EGFR mutation have not
been comprehensively analysed. Here we performed a GWAS,
followed by two validation studies, focusing on LADC with EGFR
mutations.
Results
GWAS on the risk for LADC with EGFR mutations. This study
enrolled 6,867 LADC patients, all of whom were informative for
EGFR mutation status by routine diagnosis or by the methods
described in this study (Supplementary Table 1). Of the 6,867
patients, 3,173 (46.2%) were positive for EGFR mutations,
a ﬁnding consistent with previous results in Japanese patients
with LADC5. Some case and control subjects/data overlapped
with those in our previous GWAS (Supplementary Table 2).
Germline DNAs of 663 EGFR mutation-positive LADC cases
and 4,367 controls were genotyped using Illumina Omni1-Quad
and OmniExpress chips, respectively (Supplementary Table 1).
A quantile–quantile plot, generated using the results of a logistic
regression trend test (Supplementary Fig. 1A), found that the
genomic inﬂation factor (lGC) was 0.96. The lack of population
substructure between these cases and controls was validated
by principal component analysis (PCA) of the subjects
(Supplementary Fig. 1B). Genotype clusters were visually
inspected for the most strongly associated single-nucleotide
polymorphisms (SNPs), and the results indicated a low possibility
of false-positive associations resulting from genotype misclassi-
ﬁcation (Supplementary Fig. 2). In this GWAS, no locus reached
genome-wide signiﬁcance for association (that is, a logistic
regression trend of Po5 10 8) Supplementary Fig. 1C),
including loci previously reported to be associated with overall
LADC risk (Supplementary Table 2). Five SNPs in the four loci,
TP63 at 3q28, TERT at 5p15.33, BTNL2 at 6p21.3 and BPTF at
17q24.3, were found to be more strongly associated with risk for
LADC with EGFR mutation (PTrendo10 4) than other SNPs
identiﬁed in GWASs of European and Asian populations.
Validation study. To identify susceptibility loci, a validation
study was conducted using two independent sample sets; the ﬁrst
validation cohort consisted of 1,275 cases and 6,817 controls,
while the second validation cohort consisted of 1,235 cases and
3,974 controls (Supplementary Table 1). Of the 107 SNPs with
Po1 10 4 by a logistic regression trend test (PTrend) in the
GWAS, 43 were selected, with the other 64, located within the
same locus (r2 40.8), excluded. All 43 SNPs were genotyped
successfully, using multiplex PCR-based Invader assays, in the
germline DNAs of subjects in the ﬁrst validation set. Ten SNPs
showed odds ratios (Ors) in the same direction with PTrendo0.05
(Supplementary Table 3). These 10 SNPs were assayed in
the germline DNAs of subjects in the second validation set
(Supplementary Table 4). When the results of both validation sets
were combined using a ﬁxed-effects model, two SNPs, rs2179920
at 6p21.32 and rs2495239 at 6p21.1, showed signiﬁcant associa-
tions after Bonferroni correction, in addition to ﬁve SNPs at four
known LADC susceptibility loci (that is, PTrendo1.1 10 3
calculated as 0.05/43) (Table 1). When the results of the
GWAS and the validation study were combined, both novel
loci showed genome-wide signiﬁcance (rs2179920 at 6p21.32;
PTrend¼ 5.1 10 17, OR¼ 1.36 and rs2495239 at 6p21.1;
PTrend¼ 3.9 10 9, OR¼ 1.19). ORs were similar between the
GWAS and the validation studies with no heterogeneity. Thus, six
loci, represented by seven SNPs, consisting of two at previously
unidentiﬁed loci and four known loci described above, were
associated with the risk of LADC with EGFR mutation (Table 1).
There were no signiﬁcant differences in the association of these
seven SNPs with gender or smoking status, suggesting that these
loci likely affected the risk for EGFR-positive LADC, irrespective
of gender and smoking status (Supplementary Table 5).
Differential association by EGFR mutation. To assess the
differential associations of these SNPs with LADC risk according
to the presence/absence of EGFR mutations in tumour tissues,
germline DNAs of 3,694 patients diagnosed with LADC without
EGFR mutation were genotyped (Supplementary Table 1).
Case–control analysis showed that all seven SNPs showed
statistically signiﬁcant or marginal association with risk for
LADC without EGFR mutation, but with lower ORs than those
for LADC with EGFR mutation (Supplementary Fig. 3 and
Supplementary Table 6). Case–case analysis of tumours with
and without EGFR mutations showed statistically signiﬁcant
allelic differentiation for four of the seven SNPs, rs2736100,
rs3817963, rs2179920 and rs2495239, after Bonferroni correction
(Supplementary Fig. 3 and Supplementary Table 7), indicating
that these SNPs are signiﬁcantly more strongly associated with
the risk of LADC with than without EGFR mutation (that is,
PTrendo7.1 10 3 calculated as 0.05/7).
Imputation analysis of the HLA class II locus. Imputation
analyses were performed using the GWAS data for the two newly
identiﬁed loci, rs2179920 at 6p21.32 and rs2495239 at 6p21.1,
which were found to be more strongly associated with EGFR-
positive than -negative LADC. The former SNP, rs2179920,
was located in an intergenic region near the HLA-DPB1 (major
histocompatibility complex, class II, DP beta 1) gene in the
human leukocyte antigen (HLA) class II region, and was 630 kb
proximal to rs3817963, a locus in the BTNL2 gene at the border
between the HLA class II and class III regions. Therefore,
imputation analysis was performed using the Japanese HLA
imputation reference panel18 that included the HLA class II
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genes, HLA-DRB1, HLA-DQB1, HLA-DPA1 and HLA-DPB1,
as described elsewhere. A case–control study of SNPs, including
imputed ones, for EGFR-positive LADC risk revealed two
association peaks (Fig. 1a), one including rs2179920 as a top 10
SNP and the other including rs3817963 as the top SNP
(Supplementary Tables 8 and 9). The associations of both
rs2179920 and rs3817963 SNPs with risk remained after
conditioning on rs3817963 and rs2179920 genotypes,
respectively (Fig. 1b,c and Supplementary Table 10). These
results indicated that the HLA class II region contains two
independent susceptibility loci. Interestingly, assessments of the
linkage disequilibrium of the risk allele of rs2179920 with
non-synonymous SNP alleles of HLA class II genes showed that
the strongest linkage disequilibrium for rs2179920 was with the
Asp57 allele at the Glu57Asp SNP, which consists of multiple
4-digit HLA-DPB1 alleles (r2¼ 0.98 in the binary analysis)
(Supplementary Table 11). HLA-DPB1 genotyping of 255
randomly chosen GWAS cases by the Luminex method
validated that the imputation was highly accurate with a
concordance rate of 99.1% for the Glu57Asp SNP between
imputed and genotyped four-digit alleles. By contrast, rs3817963
of BTNL2 did not show signiﬁcant linkage disequilibriums
Table 1 | Associations of seven SNPs with the risk of LADC with EGFR mutation.
SNP ID Gene Allele
(risk allele)
Stage Cases Controls P-value OR (95% CI) Phet
Total RAF Total RAF
rs2736100
5p15.33
TERT T/G
(G)
GWAS* 663 0.468 4,365 0.391 2.51 10 7 1.37 (1.21–1.54)
intron 2 First validation* 1,274 0.480 6,816 0.385 8.98 10 18 1.53 (1.38–1.69)
Second validationw 1,221 0.461 3,974 0.386 3.64 10 10 1.35 (1.23–1.48)
Combined validation
studiesz
2,495 0.471 10,790 0.385 9.81 10 26 1.43 (1.34–1.53) 0.073
All studies combinedz 3,158 0.470 15,155 0.387 1.87 10 31 1.42 (1.34–1.50) 0.16
rs2853677
5p15.33
TERT T/C
(C)
GWAS* 663 0.377 4,367 0.308 2.96 10 7 1.38 (1.22–1.56)
intron 2 First validation* 1,274 0.387 6,815 0.298 1.44 10 16 1.53 (1.38–1.69)
Second validationw 1,226 0.383 3,956 0.309 5.78 10 11 1.38 (1.26–1.53)
Combined validation
studiesz
2,500 0.370 10,771 0.302 1.47 10 25 1.45 (1.35–1.56) 0.17
All studies combinedz 3,163 0.383 15,138 0.303 3.32 10 31 1.43 (1.35–1.52) 0.31
rs2179920
6p21.32
HLA-DPB1 G/A
(A)
GWAS* 663 0.222 4,365 0.174 8.53 10 5 1.34 (1.16–1.55)
intergenic First validation* 1,272 0.204 6,817 0.154 2.12 109 1.45 (1.28–1.63)
Second validationw 1,229 0.214 3,971 0.174 5.56 10 6 1.30 (1.16–1.46)
Combined validation
studiesz
2,501 0.209 10,788 0.161 1.24 10 13 1.37 (1.26–1.49) 0.22
All studies combinedz 3,164 0.211 15,153 0.165 5.05 10 17 1.36 (1.27–1.47) 0.46
rs3817963
6p21.3
BTNL2 A/G
(G)
GWAS* 663 0.388 4,365 0.327 2.33 10 5 1.30 (1.15–1.48)
intron 4 1st validation* 1,274 0.383 6,809 0.309 9.64 10 11 1.38 (1.25–1.53)
Second validationw 1,222 0.356 3,973 0.317 2.90 104 1.20 (1.09–1.32)
Combined validation
studiesz
2,496 0.370 10,782 0.312 1.05 10 12 1.29 (1.20–1.38) 0.041
All studies combinedz 3,159 0.374 15,147 0.316 1.20 10 16 1.29 (1.21–1.37) 0.12
rs7636839
3q28
TP63 G/A
(A)
GWAS* 663 0.543 4,366 0.479 1.80 10 5 1.29 (1.15–1.46)
intron 1 First validation* 1,274 0.520 6,813 0.478 9.22 10 10 1.27 (1.18–1.37)
Second validationw 1,232 0.530 3,972 0.480 1.62 10 5 1.24 (1.12–1.38)
Combined validation
studiesz
2,506 0.525 10,785 0.479 7.08 10 9 1.21 (1.14–1.30) 0.83
All studies combinedz 3,169 0.529 15,151 0.479 9.06 10 13 1.23 (1.16–1.30) 0.63
rs7216064
17q24.3
BPTF A/G
(A)
GWAS* 663 0.759 4,367 0.706 2.05 10 5 1.35 (1.18–1.55)
intron 9 First validation* 1,275 0.741 6,817 0.708 5.54 10 5 1.24 (1.12–1.38)
Second validationw 1,231 0.749 3,974 0.703 4.34 10 5 1.25 (1.12–1.39)
Combined validation
studiesz
2,506 0.745 10,791 0.706 9.33 109 1.24 (1.15–1.34) 0.97
All studies combinedz 3,169 0.748 15,158 0.706 1.51 10 12 1.27 (1.19–1.35) 0.58
rs2495239 FOXP4 G/A
(A)
GWAS* 663 0.448 4,366 0.374 8.40 10 7 1.34 (1.19–1.51)
6p21.1 intergenic First validation* 1,273 0.413 6,817 0.383 5.21 10 3 1.15 (1.04–1.26)
Second validationw 1,231 0.422 3,966 0.387 4.70 10 3 1.15 (1.04–1.26)
Combined validation
studiesz
2,504 0.417 10,783 0.385 7.25 10 5 1.15 (1.07–1.23) 0.99
All studies combinedz 3,167 0.424 15,149 0.382 3.92 109 1.19 (1.12–1.26) 0.069
CI, conﬁdence interval; RAF, risk allele frequency.
*Adjusted for age, gender and smoking status.
wAdjusted for gender and smoking status.
zCombined meta-analysis was performed using a ﬁxed-effects model.
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with non-synonymous SNPs of any HLA genes. In the GWAS
cohort, the imputed variation at amino-acid residue 57 in
HLA-DPB1 showed a similar association with risk (PTrend¼
6.0 10 4) as rs2179920 (PTrend¼ 2.6 10 4). On the other
hand, none of the imputed HLA-DPB1 alleles showed weaker
associations than the marker SNP, rs2179920, and the Glu57Asp
SNP (Supplementary Table 12). The amino-acid residue 57,
which is located in one of the two extracellular domains of the
HLA-DPB1 protein, does not make contact with antigen
peptides19,20. Thus, the mechanism determining how the HLA-
DPB1 variation affects the risk of EGFR mutation-positive LADC
should be further investigated, particularly with respect
to the possibility that it affects immune responses against
EGFR-positive tumour cells.
Imputation analysis of the FOXP4 locus. Imputation analyses
was also performed for the other newly identiﬁed SNP, rs2495239
at 6p21.1, using the EAS population panel from the 1000
Genomes Project database21 (phase III). Twenty-four imputed
and genotyped SNPs showed signiﬁcant associations with risk of
EGFR-positive LADC (PTrendo10 4) (Fig. 2 and Supplementary
Table 13). Four imputed SNPs showed genome-wide signiﬁcance
for association (Fig. 2). In fact, the rs7741164 SNP, the most
strongly associated SNP, was also signiﬁcantly associated
with a higher susceptibility to EGFR mutation-positive LADC
(Supplementary Table 14), indicating that 6p21.1 is an additional
susceptibility locus. Interestingly, the rs2495239 SNP was located
B25 kb upstream of the FOXP4 (forkhead box P4) gene, which
encodes a member of the FOXP (forkhead transcription factor)
family of proteins. FOXP proteins play key roles in cell cycle
regulation and oncogenesis. Furthermore, meta-analysis, including
those of studies in Japan and ﬁve other Asian countries, revealed
that the FOXP4 SNP, rs7741164, is associated with a higher risk of
lung cancer risk among never-smoking Asian females22, consistent
with the aetiology of EGFR mutation-positive LADC4. Levels of
FOXP4 mRNA expression in 403 non-cancerous lung tissues, as
determined by real-time quantitative PCR, differed according to
the rs2495239 SNP (P by the linear regression test¼ 0.023)
genotype, suggesting high expression from the risk (A) allele
(Supplementary Table 15). Therefore, a high level of FOXP4
mRNA associated with a risk allele may increase the risk of LADC
with EGFR mutation by promoting oncogenesis.
Discussion
This study has provided evidence for genetic susceptibility to the
development of LADC with EGFR mutation by identifying six
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susceptibility loci showing associations at genome-wide levels.
Particularly, two new loci, 6p21.32 (HLA-DPB1) and 6p21.1
(FOXP4), and two known loci, 5p15.33 (TERT) and 6p21.3
(BTNL2), were revealed to be more preferentially associated
with risk of EGFR-positive than EGFR-negative LADC. The
re-discovery of the TERT and BTNL2 loci is highly consistent
with the fact that they these loci show strong associations with
overall LADC risk, particularly in East Asians10,11,14–16,22, that is,
populations containing LADC cases with EGFR mutations.
Further functional studies and genetic studies of other Asian
and non-Asian populations are needed to clarify how these
loci affect susceptibility to EGFR mutation-positive LADC.
EGFR-positive LADC is more prevalent in East Asian than in
European/American countries. Interestingly, the risk allele
frequencies of several of the SNPs identiﬁed in this study,
such as rs2495239 upstream of FOXP4 (0.38 versus 0.08 in
Supplementary Table 16), are different between Asians and
Europeans. These differences may help elucidate the aetiology of
LADC, including inter-ethnic variations.
Methods
Study design and subjects. A three-stage GWAS of LADCs with EGFRmutations
in the Japanese population was performed using independent samples. The
characteristics of each case–control group are shown in Supplementary Table 1.
The discovery GWAS samples consisted of 663 cases from the National Cancer
Center Hospital (NCCH) and 4,367 controls from the BioBank Japan project23 and
the Osaka-Midosuji Rotary Club (MRC). The BioBank Japan project (see URLs),
started in 2003, is a collaborative network of 66 hospitals throughout Japan that has
collected genomic DNA, serum and clinical information from 300,000 patients to
date diagnosed with any of 47 diseases to date. The MRC subjects were 988 healthy
volunteers. Individuals with any cancer were excluded from the control group.
The validation study consisted of two independent cohorts. The ﬁrst validation
cohort included 1,275 patients with LADCs with EGFR mutations and 6,817
controls. The case subjects were 1,056 from the NCCH and 219 from Kanagawa
Cancer Center. All control subjects were from the BioBank Japan project.
Individuals with any cancer were excluded from the control group. The second
validation cohort included 1,235 patients with LADCs with EGFR mutations and
3,974 controls (cancer-free volunteers) from the NCCH, Keio University, Tokyo
and the Japan PGx Data Science Consortium (JPDSC)24. JPDSC subjects were
obtained from 10 geographic regions in Japan. Of the case subjects, 900 were from
the NCCH, 136 from Akita University Hospital and 199 from Gunma University
Hospital. Of the control subjects, 2,823 were from JPDSC, 368 from NCCH and
783 from Keio University. Individuals with any cancer were excluded from the
control group.
In addition, we conducted case–control studies consisting of 3,694 patients with
LADCs without EGFR mutations and the same 15,158 controls described above.
Case subjects included 3,148 from the NCCH, 117 from Kanagawa Cancer Center,
207 from Akita University Hospital and 224 from Gunma University Hospital.
Smoking history of cases and controls was obtained via interview using a
questionnaire. Smokers were deﬁned as those who had smoked regularly for 12
months or longer at any time in their life, whereas non-smokers were deﬁned as
those who had not. All LADCs were diagnosed by cytological and/or histological
examination according to the WHO classiﬁcation. NCCH case subjects in the
GWAS and ﬁrst validation sets consisted of cases having sufﬁcient DNA for
large-scale SNP analyses. Case subjects in the second validation set consisted of
cases with smaller amounts of DNA, because, for example, only small quantities of
non-cancerous tissues were available for DNA extraction. Genome-wide typing
data of control subjects obtained before and after 2010 were used for the GWAS
and the ﬁrst validation study below, respectively. All the participants provided
written informed consent. This project was approved by the ethics committees of
all participating institutions, that is, BioBank Japan, the NCCH, JPDSC, Keio
University, Kanagawa Cancer Center, Gunma University Hospital and Akita
University Hospital.
Sample preparation and genotyping. Genomic DNA was extracted from
peripheral blood leukocytes or non-cancerous lung tissues using QIAmp DNA
Blood Maxi/QIAmp DNA Mini kits (Qiagen, Germany), according to the
manufacturer’s instructions.
In the GWAS, 678 cases of LADCs with EGFR mutations from the NCCH were
genotyped using the Illumina HumanOmni1-Quad Chip. Controls in the GWAS
consisted of 4,896 individuals with cerebral aneurysms, chronic obstructive
pulmonary disease or glaucoma; these samples were genotyped using the Illumina
Human OmniExpress Genotyping BeadChip. The genotype concordance rate
between these two genotyping platforms has been shown to be 499% (ref. 10).
In the ﬁrst validation cohort, 1,275 cases of LADC with EGFR mutation were
genotyped using the multiplex PCR-based Invader assay (Third Wave
Technologies), as described16. Controls consisted of 6,817 individuals with
epilepsy, nephrosis syndrome, atopic dermatitis, urinary tract stone disease or
Basedow’s disease; these DNA samples were genotyped using the Illumina Human
OmniExpress Genotyping BeadChip. The same quality control criteria were
applied as for GWAS (see below) to conﬁrm that none of the control subjects in the
ﬁrst validation set was an unexpected duplicate or probable relative of a control
subject in the GWAS. SNPs subjected to the ﬁrst validation test were selected by
using a cutoff PTrend value o1 10 4, because associations of SNPs with ORs
41.3 and minor allele frequencies 40.3 were predicted to be detected with a
statistical power 40.6.
In the second validation cohort, 1,235 cases of LADCs with EGFR mutations
and 3,974 controls were genotyped using the TaqMan method or HumanOmni2.5
BeadChip kit, according to the manufacturer’s protocol.
Genotyping of four-digit HLA-DPB1 alleles was performed on randomly chosen
255 GWAS LADC cases by using a WAKFlow HLA typing kit (Wakunaga
Pharmaceutical, Tokyo, Japan) together with the Luminex Multi-Analyte Proﬁling
system (ThermoFisher Scientiﬁc, Waltham, MA) according to the manufacturers’
instructions.
Quality control of GWAS data sets. Standard quality control was performed on
scans, excluding those of individuals with gender discrepancies, low call rates
(o99%) or extremely out of Hardy–Weinberg equilibrium (that is, Po1.0 10 6),
as previously described14. If any ﬁrst-degree pairs of relatives were apparent, the
control was removed from a case–control pair; otherwise, the individual with the
lower call rate was excluded. In addition, PCA was performed on the genotype data
of the samples and on European (CEU), African (YRI), and east Asian (Japanese
(JPT) and Han Chinese (CHB)) individuals obtained from the Phase II HapMap
database using smartpca25. PCA revealed no evident population substructure and
identiﬁed outliers for exclusion. Most subjects fell into a known main cluster
(Hondo) of the Japanese population. The remaining 5,030 subjects, consisting of
663 cases with EGFR mutations and 4,367 control subjects, were used for GWAS.
We also selected 631 cases without EGFR mutations based on the same criteria
(Supplementary Table 1).
Detection of EGFR mutations. DNA samples from tumour tissues were screened
for somatic mutations in EGFR exons 19 and 21 by high-resolution melting (HRM)
analysis26, invader assay27, SCORPION-ARMS28 or the PNA PCR clamp method29
in this study30. EGFR mutation tests were carried out by several methods:
PCR-Invader assay by BML Inc. (Tokyo, Japan); PNA-LNA PCR clamp assay by
Mitsubishi Chemical Medience Corp. (Tokyo, Japan); Scorpion ARMS assay by
SRL Inc. (Tokyo, Japan); and HRM assay by ourselves. The HRM assay was carried
out using primer set A for detection of EGFR mutation in exon 19 and primer set B
for detection of EGFR mutation in exon 21. The sequences of the primer set A were
50-AAAATTCCCGTCGCTATC-30 (forward) and 50-AAGCAGAAACTCACA
TCG-30 (reverse). The sequences of the primer set B were 50-AGATCACAGATT
TTGGGC-30 (forward) and 50-ATTCTTTCTCTTCCGCAC-30 (reverse). These
primers were designed by the Primer 3 software31, UCSC Genome Browser32 and
BLAT analyses33. Tumour samples were obtained from cytological specimens,
frozen tumour specimens and formalin-ﬁxed, parafﬁn-embedded tissues.
Imputation. We performed two separate imputation analyses; one was imputation
of the HLA region using the Japanese speciﬁc reference panel18 and the other
was a regional imputation using EAS references from the 1000 Genomes Project
(Phase III).
In the HLA imputation, 939 control subjects were excluded from the GWAS
study because they had been used to construct the Japanese reference panel. The
imputation included two- and four-digit classical HLA alleles and amino-acid
polymorphisms of class I and class II HLA genes, as well as additional SNPs18.
Next, imputed data at 6p21.1 were obtained using the 1000 Genomes Phase 3 EAS
reference panel. Shapeit2 (version 2.778)34 was used for pre-phasing and Minimac2
(stamped 2014.9.15)35 was used for imputation. In this analysis, data of all control
subjects from the GWAS study were used. The EAS reference panel was prepared as
follows; data for East Asian samples (CDX, CHB, CHS, JPT and KHV) were extracted
from the 1000 Genomes phase 3 v5 reference vcf ﬁle. Then, monomorphic or
singleton sites, multiallelic sites and sites with P values obtained by the Hardy–
Weinberg equilibrium testo10 6 were excluded. After imputation, poorly imputed
SNPs deﬁned by RSQRo0.70 were further excluded. Logistic regression analysis was
performed by mach2dat software36 (version 1.0.24) using imputed dosage as an
explanatory variable under the additive genetic model. LocusZoom was used to draw
regional association plots37. HaploReg v4.1 (ref. 38) was used to examine whether
putative functional SNPs are present in the susceptibility loci.
Statistical analysis. In GWAS and the validation study set 1, the strength of
association between SNPs and EGFR mutation-positive and -negative LADC was
measured as ORs adjusted for gender, age (continuous) and smoking status (never
or ever smoker) using an unconditional logistic regression analysis. In validation
study set 2, ORs adjusted for gender and smoking status (never or ever smoker)
were calculated. Combined analysis was performed using a ﬁxed-effects model.
Heterogeneity among studies was examined using the Breslow–Day test. The R
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statistical environment version 2.6.1 (ref. 39), the JMP version 11.0 or PLINK1.06
(ref. 40) was used for statistical analyses.
Association study of the rs7741164 SNP. Genotype status of the rs7741164 SNP
was imputed on all GWAS cases and controls, and 2,823 of the validation set 2
controls (Supplementary Table 1). The RSQR values, indicating imputation quality,
were 40.8. The remaining samples, consisting of 2,510 cases (all validation set 1
cases and set 2 cases) and 7,968 controls (all validation set 1 controls and the
remaining 1,151 validation set 2 controls), were genotyped using the invader assay
or TaqMan method. These data were subjected to an association analysis, the
results of which are shown in Supplementary Table 14.
Expression analysis of non-cancerous lung tissues. In all, 403 non-cancerous
lung tissue samples were obtained from LADC patients undergoing resection at the
NCCH. Total RNA was extracted from grossly dissected, snap-frozen tissue
samples using TRIzol (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s instructions. cDNA was synthesized using the SuperScript III
ﬁrst-strand synthesis system for reverse-transcription (RT)–PCR (Invitrogen) with
random hexamers. Quantitative real-time (RT)–PCR analysis for FOXP4 was
performed on duplicate samples using the ABI PRISM 7900HT (Applied Biosys-
tems, Foster City, CA, USA) with TaqMan primer and probe sets (Assay ID:
Hs01055269_m1) from Applied Biosystems. Relative expression levels for each
gene were normalized to that of GAPDH (catalogue# 4326317E, Applied Biosys-
tems) and digitized according to the mean of two values. Linear trends between
expression levels of FOXP4 mRNA and increases in the number of risk alleles were
tested in a multivariate linear regression model using JMP version 11.0 software
(SAS Institute Inc., Cary, NC). The variables used for adjustment in each test were
age (continuous), gender (male or female) and smoking status (never versus ever).
A P valueo0.05 by a multivariate linear regression test was considered statistically
signiﬁcant.
Data availability. All data in the GWAS analyses are available in Integrative
Disease Omics Database (https://gemdbj.ncc.go.jp/omics/docs/others.html), under
accession code GWAS031.
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